SFPM(SZ:002737)2024-08-28 08:56Group 1: Company Performance and Strategy - In the first half of 2024, the company achieved breakthroughs in R&D, ensuring a strong pipeline for future products despite a decline in operational indicators compared to the same period in 2023 [41] - The company has implemented strategic procurement and project management to stabilize raw material costs and enhance product quality and user experience [41] - The long-term development trend remains positive, supported by effective implementation of operational strategies [41] Group 2: Future Product Outlook - The company is focusing on a multi-faceted R&D approach, including "buy, modify, collaborate, research, and substitute" to acquire high-quality products [41] - New products such as liver protection tablets and pediatric cough syrup have received registration approval, with several other products in various stages of development [41] - The launch of these products is expected to significantly boost the company's revenue [41] Group 3: Dividend Policy - The company has maintained a high cash dividend ratio, with cumulative cash dividends of 2.651 billion since its listing, significantly exceeding the initial financing amount [41] - In 2023, the total cash dividend was 876 million, accounting for 78.27% of the net profit attributable to shareholders [41] - The company aims to continue providing high returns to investors while considering operational needs and future growth [41] Group 4: Market Trends and Preparedness - The company anticipates a peak in respiratory diseases during the autumn and winter seasons, with channels preparing inventory in advance to ensure smooth supply [41] - The seasonal characteristics of respiratory diseases indicate a high demand for related medications during this period [41]